TY - JOUR
T1 - Approaches to CNS drug delivery with a focus on transporter-mediated transcytosis
AU - Abdul Razzak, Rana
AU - Florence, Gordon John
AU - Gunn-Moore, Francis James
N1 - Funding: Alzheimer’s Scotland, Alzheimer’s Society, Rosetrees Trust and RS MacDonald Charitable Trust.
PY - 2019/6/25
Y1 - 2019/6/25
N2 - Drug delivery to the central nervous system (CNS) conferred by brain barriers is a major obstacle in the development of effective neurotherapeutics. In this review, a classification of current approaches of clinical or investigational importance for the delivery of therapeutics to the CNS is presented. This classification includes the use of formulations administered systemically that can elicit transcytosis-mediated transport by interacting with transporters expressed by transvascular endothelial cells. Neurotherapeutics can also be delivered to the CNS by means of surgical intervention using specialized catheters or implantable reservoirs. Strategies for delivering drugs to the CNS have evolved tremendously during the last two decades, yet, some factors can affect the quality of data generated in preclinical investigation, which can hamper the extension of the applications of these strategies into clinically useful tools. Here, we disclose some of these factors and propose some solutions that may prove valuable at bridging the gap between preclinical findings and clinical trials.
AB - Drug delivery to the central nervous system (CNS) conferred by brain barriers is a major obstacle in the development of effective neurotherapeutics. In this review, a classification of current approaches of clinical or investigational importance for the delivery of therapeutics to the CNS is presented. This classification includes the use of formulations administered systemically that can elicit transcytosis-mediated transport by interacting with transporters expressed by transvascular endothelial cells. Neurotherapeutics can also be delivered to the CNS by means of surgical intervention using specialized catheters or implantable reservoirs. Strategies for delivering drugs to the CNS have evolved tremendously during the last two decades, yet, some factors can affect the quality of data generated in preclinical investigation, which can hamper the extension of the applications of these strategies into clinically useful tools. Here, we disclose some of these factors and propose some solutions that may prove valuable at bridging the gap between preclinical findings and clinical trials.
KW - CNS-targeted drug delivery
KW - Blood-brain barrier
KW - Receptor-mediated transcytosis
KW - Transient BBB disruption
KW - Efflux-pump inhibition
KW - Ring-opening metathesis polymerization
UR - https://www.mdpi.com/1422-0067/20/12/3108
U2 - 10.3390/ijms20123108
DO - 10.3390/ijms20123108
M3 - Article
SN - 1422-0067
VL - 20
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 12
M1 - 3108
ER -